

Appl. No. 10/748,887
 Amdt. Dated June 12, 2007
 Reply to Office Action of April 12, 2007

RECEIVED
 CENTRAL FAX CENTER

JUN 12 2007

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence, and attachments, if any, are being facsimile transmitted to Group Art Unit 1647 of the USPTO at fax number (571) 273-8300 on March 14, 2007.

Seth J. Enger _____
 June 12, 2007
 <signature of sender> Date

REPLY UNDER 37 CFR 1.116 – Technology Center 1600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.	:	10/748,887
Applicant	:	Jürgen Engel and Manfred Peukert
Filed	:	July 30, 2002
Title	:	USE OF LHRH ANTAGONISTS IN DOSES THAT DO NOT CAUSE CASTRATION FOR THE T-CELL MEDIATED IMMUNITY
TC/A.U.	:	1646
Examiner	:	Galvez, James J.
Docket No.	:	103832-512NP

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

AMENDMENT

Sir or Madam:

This is a response to the notice of non-compliant Amendment dated April 12, 2007. This response will replace the response filed on March 14, 2007 to the non-final Official action dated September 15, 2006. It is noted that in response to the notice of non-Compliant Amendment, text to the withdrawn claims 7-11 has now been included in the listing of claims section of the current response. Applicant respectfully submits the following amendments and remarks for consideration by the Examiner in the above-identified patent application. Furthermore, a Petition for Extension of Time and the appropriate fee are enclosed. Applicant respectfully submits the following amendments and remarks for consideration by the Examiner in the above-identified patent application.

Page 1 of 14

LJBNY/4606308.1

Appl. No. 10/748,887
Amdt. Dated June 12, 2007
Reply to Office Action of April 12, 2007

RECEIVED
CENTRAL FAX CENTER

JUN 12 2007

Information Disclosure please see PTO/SB/08B form submitted herewith;

Amendments to the Specification please see replacement specification submitted herewith;

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper;

Remarks/Arguments begin on page 7 of this paper.